Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.

Bayer Announces FDA’s First Full Approval of NTRK Inhibitor

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

Pharmaceutical Technology® spoke with Alexander Seyf, CEO and co-founder of Autolomous, about the use of artificial intelligence and machine learning in pharmaceutical development and manufacturing.

Industry Outlook 2025: Technology as a Supporting Element

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

Novartis to Expand US-Based R&D and Manufacturing

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about the bio/pharmaceutical trends from 2024 that continue to impact the industry in 2025.

Industry Outlook 2025: Cell Therapy Advancement

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

Agentic AI Growth Predicted, but More Than Half of Pharma Still Resisting Change: Report

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Advancement of emerging therapies faces hurdles across all aspects and phases of drug development and manufacturing.


Navigating the Complexities of Emerging Therapy Development

Advanced solutions are improving drug dissolution, absorption, and overall therapeutic performance.

Enhancing Solubility and Bioavailability with Nanotechnology

In part two of Pharmaceutical Technology® Group's discussion with Joe Katakowski, director of Research at the RTW Foundation, the work of organizations like RTW Foundation in promoting the development of treatments for ultra-rare diseases is discussed. 

INTERPHEX 2025: Advancing Treatments for Ultra-Rare Diseases

The Pharmaceutical Technology® Group sat down with Joe Katakowski, director of Research at the RTW Foundation about the challenges involved in the development of treatments for ultra-rare diseases. 

INTERPHEX 2025: Challenges in Ultra-Rare Disease Treatment Development

Feliza Mirasol is the science editor for 

Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development